ATE346939T1 - Dsp-3, eine phosphatase mit zwei spezifizitäten - Google Patents

Dsp-3, eine phosphatase mit zwei spezifizitäten

Info

Publication number
ATE346939T1
ATE346939T1 AT00943359T AT00943359T ATE346939T1 AT E346939 T1 ATE346939 T1 AT E346939T1 AT 00943359 T AT00943359 T AT 00943359T AT 00943359 T AT00943359 T AT 00943359T AT E346939 T1 ATE346939 T1 AT E346939T1
Authority
AT
Austria
Prior art keywords
dsp
phosphatase
cell
polypeptides
agents
Prior art date
Application number
AT00943359T
Other languages
German (de)
English (en)
Inventor
Ralf M Luche
Bo Wei
Original Assignee
Ceptyr Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceptyr Inc filed Critical Ceptyr Inc
Application granted granted Critical
Publication of ATE346939T1 publication Critical patent/ATE346939T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00943359T 1999-07-02 2000-06-29 Dsp-3, eine phosphatase mit zwei spezifizitäten ATE346939T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14233899P 1999-07-02 1999-07-02
PCT/US2000/010868 WO2001002581A1 (en) 1999-07-02 2000-04-20 Dsp-3 dual-specificity phosphatase

Publications (1)

Publication Number Publication Date
ATE346939T1 true ATE346939T1 (de) 2006-12-15

Family

ID=37517972

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00943359T ATE346939T1 (de) 1999-07-02 2000-06-29 Dsp-3, eine phosphatase mit zwei spezifizitäten

Country Status (9)

Country Link
EP (2) EP1196598B1 (da)
JP (1) JP2003525027A (da)
AT (1) ATE346939T1 (da)
AU (2) AU4367600A (da)
CA (1) CA2377670A1 (da)
DE (1) DE60032145T2 (da)
DK (1) DK1196598T3 (da)
ES (1) ES2277843T3 (da)
WO (2) WO2001002581A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003507016A (ja) * 1999-08-13 2003-02-25 スージェン・インコーポレーテッド 新規な蛋白質ホスファターゼおよびホスファターゼ関連疾患の診断および治療
US6900043B1 (en) * 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
AU2002356496A1 (en) * 2001-05-16 2003-04-01 Ceptyr, Inc. Dsp-18 dual-specificity phosphatase
CA2480664A1 (en) * 2002-03-28 2003-10-09 Qlt Inc. Cancer associated protein phosphatases and their uses
CN113801156B (zh) * 2021-10-13 2022-11-15 北京大学 一种蛋白酪氨酸磷酸酶选择性抑制剂、用途、制备方法以及药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002704A2 (en) * 1997-07-08 1999-01-21 Cold Spring Harbor Laboratory Dual specifically phosphatase and methods of use
WO2000006728A2 (en) * 1998-07-28 2000-02-10 Incyte Pharmaceuticals, Inc. Phosphorylation effectors
AU4206700A (en) * 1999-04-07 2000-10-23 Ceptyr, Inc. Dsp-3 dual-specificity phosphatase
JP2003507016A (ja) * 1999-08-13 2003-02-25 スージェン・インコーポレーテッド 新規な蛋白質ホスファターゼおよびホスファターゼ関連疾患の診断および治療
US6900043B1 (en) * 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways

Also Published As

Publication number Publication date
JP2003525027A (ja) 2003-08-26
WO2001002581A1 (en) 2001-01-11
EP1772517A3 (en) 2007-04-18
ES2277843T3 (es) 2007-08-01
AU4367600A (en) 2001-01-22
EP1196598A1 (en) 2002-04-17
DE60032145D1 (de) 2007-01-11
EP1196598B1 (en) 2006-11-29
DK1196598T3 (da) 2007-04-02
AU5783800A (en) 2001-01-22
EP1772517A2 (en) 2007-04-11
CA2377670A1 (en) 2001-01-11
DE60032145T2 (de) 2007-10-25
WO2001002582A1 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
ATE188256T1 (de) Oberflächenlokalisierte expression von enzymen in gengesteuerter prodrugtherapie
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
EP2236153A3 (en) Compositons and methods for treating cardiac conditions
ES2056294T3 (es) (quinolin-2-il-metoxi)fenil-acil-sulfonamidas y -cianamidas substituidas, procedimiento para su obtencion y su empleo en medicamentos.
DE59010347D1 (de) Substituierte N-(Chinolin-2-yl-methoxy)benzylsulfonylharnstoffe
BR9913190A (pt) Modulação de proteìnas quinase de linhagemmúltipla
ATE346939T1 (de) Dsp-3, eine phosphatase mit zwei spezifizitäten
MXPA04001720A (es) Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
DE69022778D1 (de) Zellkultursubstrat, Bioreaktor mit Zellkultursubstrat und therapeutische Vorrichtung vom extrakorporalen Umlauftyp.
Allan et al. Cyclic AMP-dependent and-independent effects on tissue-type plasminogen activator activity in osteogenic sarcoma cells; evidence from phosphodiesterase inhibition and parathyroid hormone antagonists
WO2000060092A3 (en) Dsp-3 dual-specificity phosphatase
WO2002024740A3 (en) Dsp-15 dual-specificity phosphatase
WO2001083723A3 (en) Dsp-14 dual-specificity phosphatase
WO2002026997A3 (en) Dsp-16 dual-specificity phosphatase
WO2003025196A3 (en) Dsp-18 dual-specificity phosphatase
WO2001057221A3 (en) Dsp-12 and dsp-13 dual-specificity phosphatases
WO2000053636A3 (en) Dsp-1 dual-specificity map kinase phosphatase
WO2004016739A3 (en) Cell modulation using a cytoskeletal protein
DK0428860T3 (da) Substituerede (quinolin-2-yl-methoxy)phenyl-carbonylurinstoffer
WO2002014536A3 (en) Odulating multiple lineage kinase proteins
ES2067694T3 (es) Enzima soportada.
DE3484912D1 (de) Peptidderivate und deren verwendung als substrate zur quantitativen bestimmung von enzymen.
ES8800139A2 (es) Mejoras introducidas en el objeto de la patente principal por un procedimiento para la preparacion de derivados de urea.
DE68915216D1 (de) Substrate zur Bestimmung der enzymatischen Aktivität.
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1196598

Country of ref document: EP

REN Ceased due to non-payment of the annual fee